These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 12201326

  • 1. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel.
    Endrikat J, Blode H, Gerlinger C, Rosenbaum P, Kuhnz W.
    Eur J Contracept Reprod Health Care; 2002 Jun; 7(2):79-90. PubMed ID: 12201326
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W, Staks T, Jütting G.
    Contraception; 1994 Dec; 50(6):563-79. PubMed ID: 7705098
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations.
    Carol W, Klinger G, Jäger R, Kasch R, Brandstädt A.
    Exp Clin Endocrinol; 1992 Dec; 99(1):12-7. PubMed ID: 1628691
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.
    Kuhnz W, al-Yacoub G, Fuhrmeister A.
    Contraception; 1992 Nov; 46(5):455-69. PubMed ID: 1458892
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W, Baumann A, Staks T, Dibbelt L, Knuppen R, Jütting G.
    Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
    [Abstract] [Full Text] [Related]

  • 6. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.
    Skouby SO, Endrikat J, Düsterberg B, Schmidt W, Gerlinger C, Wessel J, Goldstein H, Jespersen J.
    Contraception; 2005 Feb; 71(2):111-7. PubMed ID: 15707560
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL, Menard J, Rad M, Burggraaf J, de Kam ML, Tokay BA, Sivin I, Kluft C.
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and protein binding of gestodene under treatment with a low-dose combination oral contraceptive for three months.
    Dibbelt L, Knuppen R, Kuhnz W, Jütting G.
    Arzneimittelforschung; 1992 Sep; 42(9):1146-52. PubMed ID: 1445484
    [Abstract] [Full Text] [Related]

  • 9. A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 microg of ethinylestradiol and 100 microg of levonorgestrel with 30 microg of ethinylestradiol and 100 microg of levonorgestrel.
    Jespersen J, Endrikat J, Düsterberg B, Schmidt W, Gerlinger C, Wessel J, Sidelmann JJ, Skouby SO.
    Contraception; 2005 Aug; 72(2):98-104. PubMed ID: 16022847
    [Abstract] [Full Text] [Related]

  • 10. The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1.
    Pakarinen P, Lähteenmäki P, Rutanen EM.
    Acta Obstet Gynecol Scand; 1999 May; 78(5):423-8. PubMed ID: 10326889
    [Abstract] [Full Text] [Related]

  • 11. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne.
    Palatsi R, Reinilä M, Kivinén S.
    Acta Derm Venereol; 1986 May; 66(3):225-30. PubMed ID: 2426899
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles.
    Kuhnz W, Staks T, Jütting G.
    Contraception; 1993 Dec; 48(6):557-75. PubMed ID: 8131397
    [Abstract] [Full Text] [Related]

  • 13. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives.
    Palatsi R, Hirvensalo E, Liukko P, Malmiharju T, Mattila L, Riihiluoma P, Ylöstalo P.
    Acta Derm Venereol; 1984 Dec; 64(6):517-23. PubMed ID: 6084924
    [Abstract] [Full Text] [Related]

  • 14. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
    Griffith SG, Dai Y.
    Clin Ther; 2004 Dec; 26(12):2056-65. PubMed ID: 15823769
    [Abstract] [Full Text] [Related]

  • 15. Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene.
    Lepot MR, Gaspard UJ.
    Int J Fertil; 1987 Dec; 32 Suppl():15-20. PubMed ID: 2906343
    [Abstract] [Full Text] [Related]

  • 16. Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women.
    Blode H, Foidart JM, Heithecker R.
    Eur J Contracept Reprod Health Care; 2001 Sep; 6(3):167-71. PubMed ID: 11763981
    [Abstract] [Full Text] [Related]

  • 17. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers.
    Blode H, Wuttke W, Loock W, Röll G, Heithecker R.
    Eur J Contracept Reprod Health Care; 2000 Dec; 5(4):256-64. PubMed ID: 11245553
    [Abstract] [Full Text] [Related]

  • 18. Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial.
    Archer DF, Stanczyk FZ, Rubin A, Foegh M.
    Contraception; 2012 Jun; 85(6):595-601. PubMed ID: 22133660
    [Abstract] [Full Text] [Related]

  • 19. Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties.
    Hammond GL, Abrams LS, Creasy GW, Natarajan J, Allen JG, Siiteri PK.
    Contraception; 2003 Feb; 67(2):93-9. PubMed ID: 12586319
    [Abstract] [Full Text] [Related]

  • 20. Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins.
    White T, Ozel B, Jain JK, Stanczyk FZ.
    Contraception; 2006 Oct; 74(4):293-6. PubMed ID: 16982228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.